1. Home
  2. FSP vs CRDL Comparison

FSP vs CRDL Comparison

Compare FSP & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Street Properties Corp.

FSP

Franklin Street Properties Corp.

HOLD

Current Price

$0.93

Market Cap

100.4M

Sector

Real Estate

ML Signal

HOLD

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

HOLD

Current Price

$1.02

Market Cap

97.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSP
CRDL
Founded
1981
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
100.4M
97.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FSP
CRDL
Price
$0.93
$1.02
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$9.00
AVG Volume (30 Days)
479.0K
649.2K
Earning Date
10-28-2025
11-13-2025
Dividend Yield
4.39%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$109,497,000.00
N/A
Revenue This Year
$4.36
N/A
Revenue Next Year
$0.81
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$0.77
52 Week High
$2.09
$1.59

Technical Indicators

Market Signals
Indicator
FSP
CRDL
Relative Strength Index (RSI) 34.42 48.53
Support Level $0.95 $0.88
Resistance Level $1.01 $1.12
Average True Range (ATR) 0.05 0.07
MACD 0.01 0.00
Stochastic Oscillator 22.48 58.09

Price Performance

Historical Comparison
FSP
CRDL

About FSP Franklin Street Properties Corp.

Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Share on Social Networks: